Xintela AB (publ) announced that the results from Xintela's preclinical EQSTEM study in horses with post-traumatic osteoarthritis (OA) have been published in the scientific journal Cartilage. The results demonstrate less pain and less cartilage damage after treatment with the stem cell product EQSTEM, indicating a disease modifying effect of EQSTEM. Xintela has previously published that integrin a10b1-selected stem cells from horses, EQSTEM, which are the equivalent of the human stem cell product XSTEM®?, reduce cartilage and bone damage in a post-traumatic OA model in horses (Delco et al., Am J Sports Med.

2020;48:612). The study results that now have been published in the scientific Journal, further support a disease modifying effect of EQ STEM by Cartilage showing significantly less cartilage damage in treated horses compared to untreated horses. In addition, EQSTEM significantly reduced lameness in treated horses which indicates less pain and improved function of the treated joint.

The results also demonstrated that specific biological factors were increased in the joint after injection of EQSTEM which provide further understanding of the mechanisms of action of EQSTEM. The study was conducted in collaboration with the University of Copenhagen.